About OriCiro Genomics
OriCiro Genomics is a company based in Tokyo (Japan) founded in 2018 was acquired by Moderna in January 2023.. OriCiro Genomics has raised $10.87 million across 4 funding rounds from investors including Moderna, Asahi Kasei and UT-EC Japan. OriCiro Genomics operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Ginkgo Bioworks and Twist Bioscience, among others.
- Headquarter Tokyo, Japan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of OriCiro Genomics
OriCiro Genomics has successfully raised a total of $10.87M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(08 Apr 2019)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series B - OriCiro Genomics | Valuation |
investors |
|
| Jul, 2021 | Amount | Series B - OriCiro Genomics | Valuation | UTEC | |
| Jul, 2021 | Amount | Debt – Conventional - OriCiro Genomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OriCiro Genomics
OriCiro Genomics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Moderna, Asahi Kasei and UT-EC Japan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and Early stage VC firm investing in Japan
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OriCiro Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OriCiro Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oriciro Genomics Comparisons
Competitors of OriCiro Genomics
OriCiro Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks and Twist Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of renewable products for industrial solutions
|
|
| domain | founded_year | HQ Location |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| domain | founded_year | HQ Location |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oriciro Genomics
Frequently Asked Questions about OriCiro Genomics
When was OriCiro Genomics founded?
OriCiro Genomics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is OriCiro Genomics located?
OriCiro Genomics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Is OriCiro Genomics a funded company?
OriCiro Genomics is a funded company, having raised a total of $10.87M across 4 funding rounds to date. The company's 1st funding round was a Series B of $7.29M, raised on Apr 08, 2019.
What does OriCiro Genomics do?
OriCiro Genomics was established in 2018 in Tokyo, Japan, within the biotechnology sector. Focus is placed on developing technologies for DNA synthesis and amplification. The OriCiro Cell-Free Cloning System is provided, consisting of the OriCiro Assembly Kit and OriCiro Amp Kit. Cell-free assembly and amplification of circular DNA molecules are facilitated through this system, supporting genomic research and applications. Operations are centered in Japan, with a domain at oriciro.com.
Who are the top competitors of OriCiro Genomics?
OriCiro Genomics's top competitors include Syngenta, Synthego and Nuclera Nucleics.
Who are OriCiro Genomics's investors?
OriCiro Genomics has 5 investors. Key investors include Moderna, Asahi Kasei, UT-EC Japan, ITV, and JFC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.